Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07433621 · ClinicalTrials.gov registry record · Phase 1
Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency
A Phase 1 study of XIAP Deficiency, sponsored by Children's Hospital Medical Center, Cincinnati.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT07433621 is a Phase 1 study of XIAP Deficiency that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07433621, a Phase 1 study of XIAP Deficiency, is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate safety and tolerability of oral quercetin in reducing inflammation in male patients with XIAP deficiency. Quercetin is a naturally occurring antioxidant that has many properties including the ability to decrease inflammation in other diseases.
Conditions Studied
Interventions
- DRUG Quercetin
Study Locations (1)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-03 |
| Est. Completion | 2029-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07433621
The ClinicalTrials.gov registry entry for NCT07433621 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with XIAP Deficiency appearing as the primary indexed condition, and to 1 intervention - of which Quercetin is the first listed.
NCT07433621 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT07433621 about?
NCT07433621 is a clinical study titled "Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency". The purpose of the study is to evaluate safety and tolerability of oral quercetin in reducing inflammation in male patients with XIAP deficiency. Quercetin is a naturally occurring antioxidant that has many properties including the ability to decrease inflammation in other diseases.
What is the current status of trial NCT07433621?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2026-03. Estimated completion is 2029-06.
What conditions does trial NCT07433621 study?
This clinical trial studies the following conditions: XIAP Deficiency.
What interventions are being tested in trial NCT07433621?
The interventions under investigation include: Quercetin (DRUG).
Who is sponsoring clinical trial NCT07433621?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07433621 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.